Immunologic features of nontuberculous mycobacterial pulmonary disease based on spatially resolved whole transcriptomics
- PMID: 39138424
- PMCID: PMC11323347
- DOI: 10.1186/s12890-024-03207-2
Immunologic features of nontuberculous mycobacterial pulmonary disease based on spatially resolved whole transcriptomics
Abstract
Background: The immunologic features of nontuberculous mycobacterial pulmonary disease (NTM-PD) are largely unclear. This study investigated the immunologic features of NTM-PD using digital spatial profiling techniques.
Methods: Lung tissues obtained from six patients with NTM-PD between January 1, 2006, and December 31, 2020, at Seoul National University Hospital were subjected to RNA sequencing. Cores from the peribronchial areas were stained with CD3, CD68, and DNASyto13, and gene expression at the whole-transcriptome level was quantified using PCR amplification and Illumina sequencing. Lung tissues from six patients with bronchiectasis collected during the same period were used as controls. The RNA sequencing results were validated using immunohistochemistry (IHC) in another cohort (30 patients with NTM-PD and 15 patients with bronchiectasis).
Results: NTM-PD exhibited distinct gene expression patterns in T cells and macrophages. Gene set enrichment analysis revealed that pathways related to antigen presentation and processing were upregulated in NTM-PD, particularly in macrophages. Macrophages were more prevalent and the expression of genes associated with the M1 phenotype (CD40 and CD80) was significantly elevated. Although macrophages were activated in the NTM-PD group T cell activity was unaltered. Notably, expression of the costimulatory molecule CD28 was decreased in NTM-PD. IHC analysis showed that T cells expressing Foxp3 or TIM-3, which facilitate the regulatory functions of T cells, were increased.
Conclusions: NTM-PD exhibits distinct immunologic signatures characterized by the activation of macrophages without T cell activation.
Keywords: Lung disease; M1 phenotype; Macrophage activation; Nontuberculous mycobacteria.
© 2024. The Author(s).
Conflict of interest statement
Dr. JJ Yim has served as the overall or institutional principal investigator for clinical trials related to non-tuberculous mycobacterial pulmonary disease sponsored by LigaChem Biosciences, Insmed and AN2 Therapeutics. Additionally, he has received several drugs free of charge as a principal investigator for previous trials related to tuberculosis from Pfizer, Otsuka, and Yuhan.
Figures






Similar articles
-
PARK2 as a susceptibility factor for nontuberculous mycobacterial pulmonary disease.Respir Res. 2024 Aug 14;25(1):310. doi: 10.1186/s12931-024-02946-4. Respir Res. 2024. PMID: 39143598 Free PMC article.
-
Metabolomic Characteristics of Nontuberculous Mycobacterial Pulmonary Disease.J Infect Dis. 2024 Oct 16;230(4):797-806. doi: 10.1093/infdis/jiae100. J Infect Dis. 2024. PMID: 38407452
-
Clinical Efficacy of Serum Antiglycopeptidolipid Core IgA Antibody Test for Screening Nontuberculous Mycobacterial Pulmonary Disease in Bronchiectasis: A European Multicenter Cohort Study.Chest. 2025 May;167(5):1300-1310. doi: 10.1016/j.chest.2024.10.029. Epub 2024 Oct 28. Chest. 2025. PMID: 39490969 Free PMC article.
-
Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary disease and tuberculosis in a referral hospital in Japan.Respir Med. 2019 Jun;152:74-80. doi: 10.1016/j.rmed.2019.05.001. Epub 2019 May 8. Respir Med. 2019. PMID: 31128614 Review.
-
Risk Factors for Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Literature Review and Meta-Analysis.Chest. 2023 Nov;164(5):1115-1124. doi: 10.1016/j.chest.2023.06.014. Epub 2023 Jun 17. Chest. 2023. PMID: 37429481
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials